ID

25033

Description

Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease

Mots-clés

Versions (2)
  1. 24/08/2017 24/08/2017 -
  2. 04/09/2017 04/09/2017 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

24 août 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

end of study determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

Anglais

end of study determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 Formulaires  
Administrative Data
Description

Administrative Data

Alias
UMLS CUI-1
C1320722
Patient Initials
Description

patient's initials

Type de données

text

Alias
UMLS CUI [1]
C2986440
Patient No.
Description

patient number

Type de données

integer

Alias
UMLS CUI [1]
C1830427
Date of Visit
Description

date of visit

Type de données

date

Alias
UMLS CUI [1]
C1320303
COMPLETION OF TREATMENT PHASE
Description

COMPLETION OF TREATMENT PHASE

Alias
UMLS CUI-1
C0580352
Date of termination
Description

date of study termination

Type de données

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0008972
UMLS CUI [1,3]
C0013135
Did the patient remain on study drug through Day 7?
Description

patient's study participation status

Type de données

integer

Did the patient remain on study drug through Day 7?
Description

If "NO, discontinued study drug prematurely"; tick the one most significant reason below

Type de données

integer

COMPLETION THROUGH DAY 14
Description

COMPLETION THROUGH DAY 14

Alias
UMLS CUI-1
C2348568
Did the patient complete study visits/prodcedures through Day 14?
Description

patient's study participation status

Type de données

integer

Did the patient complete study visits/prodcedures through Day 14?
Description

If "NO, check the one most significant reason below", choose a reason below.

Type de données

integer

Date of last contact
Description

If "Lost to follow-up" above, record the date.

Type de données

date

Alias
UMLS CUI [1]
C0805839
PATIENT DEATH
Description

PATIENT DEATH

Alias
UMLS CUI-1
C1306577
Date of death
Description

date of death

Type de données

date

Alias
UMLS CUI [1]
C1148348
Was an autopsy performed?
Description

If YES, attach a copy of the autopsy report.

Type de données

integer

Alias
UMLS CUI [1]
C0004398
Primary cause of death
Description

primary cause of death

Type de données

text

Alias
UMLS CUI [1]
C0007465
Underlying cause(s) of death
Description

underlying causes of death

Type de données

text

Alias
UMLS CUI [1]
C0007465
Was death related to study drug?
Description

death related to study drug

Type de données

integer

Alias
UMLS CUI [1,1]
C0011065
UMLS CUI [1,2]
C0304229
INVESTIGATOR'S SIGNATURE
Description

INVESTIGATOR'S SIGNATURE

Alias
UMLS CUI-1
C2346576
Signature
Description

I have assumed reponsibility for completeness and accuracy of all data recorded on the case report forms.

Type de données

text

Date
Description

I have assumed reponsibility for completeness and accuracy of all data recorded on the case report forms.

Type de données

date

Alias
UMLS CUI [1]
C0807937
Retour au début de la page

Similar models

end of study determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
patient's initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
patient number
Item
Patient No.
integer
C1830427 (UMLS CUI [1])
date of visit
Item
Date of Visit
date
C1320303 (UMLS CUI [1])
Item Group
COMPLETION OF TREATMENT PHASE
C0580352 (UMLS CUI-1)
date of study termination
Item
Date of termination
date
C0011008 (UMLS CUI [1,1])
C0008972 (UMLS CUI [1,2])
C0013135 (UMLS CUI [1,3])
Item
Did the patient remain on study drug through Day 7?
integer
patient's study participation status
Code List
Did the patient remain on study drug through Day 7?
CL Item
YES (1)
CL Item
NO, discontinued study drug prematurely (2)
Item
Did the patient remain on study drug through Day 7?
integer
patient's study participation status
Code List
Did the patient remain on study drug through Day 7?
CL Item
Adverse event, specify AE (Adverse event must be recorded on the Adverse Events CRF.) (1)
CL Item
Patientrequest (unrelated to AE), specify  (2)
CL Item
Non-compliance(unrelatedto an AE), specify (3)
CL Item
Investigatorjudgement, specify  (4)
CL Item
Termination of patient dosing by sponsor (5)
CL Item
Protocolviolation, specify  (6)
CL Item
Death, complete the Patient Death CRF (7)
CL Item
Other, specify (8)
Item Group
COMPLETION THROUGH DAY 14
C2348568 (UMLS CUI-1)
Item
Did the patient complete study visits/prodcedures through Day 14?
integer
patient's study participation status
Code List
Did the patient complete study visits/prodcedures through Day 14?
CL Item
YES (1)
CL Item
NO, check the one most significant reason below (2)
Item
Did the patient complete study visits/prodcedures through Day 14?
integer
patient's study participation status
Code List
Did the patient complete study visits/prodcedures through Day 14?
CL Item
Death, complete the Patient Death CRF  (1)
CL Item
Lost to follow-up  (2)
CL Item
Other, specify (3)
date of last contact
Item
Date of last contact
date
C0805839 (UMLS CUI [1])
Item Group
PATIENT DEATH
C1306577 (UMLS CUI-1)
date of death
Item
Date of death
date
C1148348 (UMLS CUI [1])
Item
Was an autopsy performed?
integer
C0004398 (UMLS CUI [1])
autopsy
Code List
Was an autopsy performed?
CL Item
YES (1)
CL Item
NO (2)
primary cause of death
Item
Primary cause of death
text
C0007465 (UMLS CUI [1])
underlying causes of death
Item
Underlying cause(s) of death
text
C0007465 (UMLS CUI [1])
Item
Was death related to study drug?
integer
C0011065 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
death related to study drug
Code List
Was death related to study drug?
CL Item
YES (1)
CL Item
NO (2)
Item Group
INVESTIGATOR'S SIGNATURE
C2346576 (UMLS CUI-1)
investigator's signature
Item
Signature
text
signature date
Item
Date
date
C0807937 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial